Please join our educational programme for healthcare professionals on the diagnosis and management of CKD by participating in this survey.
This survey is the first part of the programme and is intended to determine the status quo of CKD diagnosis and management primarily in the ambulant setting. It consists of 22 questions to assess your confidence in and approach to managing CKD, as well as the infrastructure of your clinical practice. The results will be incorporated into some of the upcoming educational activities, which will include a live webinar on 19 September 2023, a publication, and a follow-up survey in Q1 2024. Furthermore, the outcome of the first survey is intended to be presented at this year´s CVOT Summit.
AstraZeneca has provided a sponsorship grant towards this independent programme.
1.
Please state your specification
2.
Please state your country
3.
How many patients with chronic kidney disease (CKD) do you see monthly?
4.
How often do you newly diagnose CKD on average per month?
5.
For the diagnosis and management of CKD, I consider myself to be…
6.
What guideline(s) is your CKD management based on?
7.
Urine albumin-creatinine ratio (UACR) is an indicator of kidney damage.
8.
Estimated glomerular filtration rate (eGFR) is an indicator of kidney function.
9.
What do you use for CKD diagnosis in your practice?
10.
Which method for measuring serum creatinine does your central laboratory use?
11.
If you use eGFR for CKD diagnosis, how do you obtain the value?
12.
If you determine albuminuria for CKD diagnosis, how do you measure it?
13.
Potential risk factors for the development of CKD are e.g., hypertension, diabetes, cardiovascular disease, obesity, and family history of kidney disease. In which individuals do you initiate CKD screening?
14.
How often do you repeat screening in individuals with risk factors?
15.
How would you proceed if the creatinine-based eGFR results are not accurate enough and further assessment of kidney function is needed?
16.
At what eGFR values do you record the diagnosis of CKD and communicate it to the patient?
17.
What do you consider to be the key pillars of CKD treatment?
18.
How often do you monitor disease progression in individuals with CKD?
19.
Which risk-prediction tools do you use?
20.
What are clinical scenarios for CKD in which you refer a patient to a nephrologist?
21.
An individual is experiencing hyperkalaemia while receiving renin–angiotensin–aldosterone inhibitor (RAASi) therapy at maximum dose (ACEi, ARB, ARNi, MRA). How do you act?
22.
What do you consider to be the biggest challenge in the management of CKD?
